Background: Global recognition of antimicrobial resistance (AMR) as an urgent public health problem has galvanized national and international efforts. Chief among these are interventions to curb the overuse and misuse of antibiotics. However, the impact of these initiatives is not fully understood, making it difficult to assess the expected effectiveness and sustainability of further policy interventions. We conducted a systematic review to summarize existing evidence for the impact of nationally enforced interventions to reduce inappropriate antibiotic use in humans.
Introduction
Antimicrobial resistance (AMR) is a major threat to global health. Without urgent action, an estimated 10 million annual deaths due to resistant pathogens are expected by 2050. 1 Among antimicrobials, bacterial resistance to antibiotics is a major concern. Antibiotic consumption is a major driver of resistance, and global antibiotic consumption is rising; a recent comprehensive assessment of antibiotic consumption has shown a 65% increase in worldwide antibiotic consumption between 2000 and 2015, from 21.1 billion to 34.8 billion DDD. 2 To counter the rise in AMR, the WHO's Global Action Plan on Antimicrobial Resistance (2015) 3 has identified responsible use as one of five key priority areas for urgent intervention, endorsing strategies to reduce both the supply of and demand for antibiotics. These include regulatory measures to reduce and optimize antimicrobial prescribing and dispensing, and campaigns to improve overall awareness and understanding of AMR, among both healthcare professionals and the general public.
Numerous interventions have been proposed and used to reduce antibiotic consumption in different settings, but the extent to which these have been implemented at a national level, and their impact, remain largely unknown. We conducted a systematic review to assess the impact of responsible use initiatives implemented at the national and/or subnational level to reduce unnecessary antibiotic consumption, in order to evaluate the available evidence on the impact of coordinated national implementations.
Methods

Inclusion and exclusion criteria
We conducted this review using PRISMA guidelines 4 (Prospero registration number: CRD42017064629). We included studies describing any nationallevel and/or subnational-level responsible use initiatives to address antibiotic resistance in the community or at the primary, secondary or tertiary care levels. Studies with no reported outcomes relating to antibiotic consumption and/or prescription were excluded. The inclusion and exclusion criteria can be found in Table 1 .
Search strategy
The literature search focused on interventions related to responsible use of antibiotics ( Table 2 ). The search strategy was developed with an information specialist and included Medical Subject Headings (MeSH) terms, keywords and free text (title and abstract) terms relating to AMR, nationallevel initiatives and their outcomes ( Table 2 ).
The search strategy was used for the databases Medline, Embase and Global Health. To ensure coverage of low-and middle-income countries (LMICs), a simplified search strategy was used for the following databases: Latin American and Caribbean Health Sciences Literature (LILACS), Africa-Wide Information, Index Medicus for the South-East Asian Region (IMSEAR), Index Medicus for the Eastern Mediterranean Region (IMEMR) and Western Pacific Rim Region Index Medicus (WPRIM). In total, seven databases were searched from inception until May 2017. No date or language restrictions were applied; however, searches were conducted in English.
Search and retrieval of studies
Two reviewers (J. M. L. and S. R. S.) independently conducted the literature search and identified relevant articles based on title and/or abstract. If either reviewer considered a study potentially eligible, the two reviewers would independently assess the full text to determine whether it met the inclusion criteria. Full text articles in languages other than English were translated into English for screening. Any disagreements were resolved by discussion with a third reviewer (D. M. C.).
Data synthesis
Three reviewers (J. M. L., S. R. S. and D. M C.) independently extracted data from included studies. Data were extracted on the following: (i) study characteristics (study design, setting); (ii) type of intervention; and (iii) results and type of outcome measure (e.g. antibiotic consumption, prescription, compliance with prescription guidelines, resistance rates). Differences in data extraction or study interpretation were resolved by discussion and consensus. Included studies were then grouped based on type of intervention conducted.
Risk of bias assessment
Three reviewers (J. M. L., S. R. S. and D. M. C.) independently assessed risk of bias. We used the Cochrane Risk of Bias Tool for Non-Randomized Studies of Interventions (ACROBAT-NRSI), since most of the intervention studies adopted a time-series design. 5 We classified studies that had low risk of bias in all domains as low overall risk of bias. Studies that had high or unclear risk of bias in one or more domains were classified as overall high or unclear risk of bias.
Results
We identified 12 718 records from the database search, and two additional records from forward searching. After removing duplicate records, 7952 articles remained. These were screened for relevance by title and abstract, yielding 68 articles that were retrieved as full texts (Figure 1 ). Thirty-four articles met the inclusion criteria, all of which were journal articles and were published in English, Chinese, French, Croatian and Spanish. We did not conduct a meta-analysis owing to heterogeneity of study design, interventions, participants and outcomes, but instead present a qualitative summary of interventions, results and outcomes.
Countries and interventions (characteristics of included studies)
The 34 included studies used quantitative methods and were conducted in 21 countries (Figures 2 and 3 ). Twenty-two studies were carried out in high-income and 12 in upper-middle-income countries as defined by World Bank classification. 6 Eight studies had high risk of bias, 20 studies had moderate risk of bias and 6 studies had low risk of bias. We classified studies into two broad domains: (i) interventions to reduce the inappropriate access to antibiotics; and (ii) interventions to reduce demand for antibiotics.
Full details of the included studies, including study design, setting and key findings, can be found in Table 3 .
Reducing inappropriate access to antibiotics
Interventions within this domain included the institution of antibiotic-specific regulations (12 studies), prescribing restrictions (10 studies), separation of drug prescribing from dispensing (2 studies) and educational campaigns for healthcare professionals (6 studies).
Institution of regulation (antibiotic committees and clinical guidelines)
Eleven studies in seven countries described establishment of national hospital antibiotic management teams as an intervention to address AMR. Responsibilities of hospital antibiotic management JAC teams included training of healthcare professionals, surveillance of antibiotic consumption, prescription review, evaluation of hospital resources for infection control and development of clinical guidelines for antibiotic prescription. Additionally, two studies in two countries described the strengthening and dissemination of clinical guidelines for the prescription of antibiotics in both inpatient and outpatient settings. Of the 11 studies, 10 found overall reductions in antibiotic use, while 1 found mixed results in terms of consumption levels; a decrease in consumption of third-generation cephalosporins after implementation of an antibiotic restriction programme was accompanied by an increase in consumption of penicillins. 7 Other outcome measures included reductions in the number of antibiotic packages consumed and/or prescribed, 8, 9 seasonal variation in fluoroquinolone use, 9 grams consumed per year, 10 antibiotic sales value and volume, 11, 12 percentage of antibiotic use by inpatients 13 as well as DDD. [13] [14] [15] [16] Three studies evaluated the link between antibiotic consumption and antibiotic resistance rates, calculated as the percentage of bacterial isolates displaying resistance, 10, 15, 17 and found mixed results. At the institutional level, two studies found increased compliance with national antibiotic prescribing guidelines as well as better key structural resources for antibiotic management and infection control in hospitals. [18] [19] [20] 
Restriction of prescribing practices
Two types of prescribing restrictions were described in 11 studies representing nine countries. The first was restrictions on reimbursement of antibiotic prescription (e.g. when antibiotics were prescribed as first-line treatment, or reduced reimbursement in general). These were described in six countries and covered the following antibiotics: methicillin, 21 amoxicillin/clavulanic acid, 22,23 third-and fourth-generation cephalosporins, 22, 24 fluoroquinolones, 22, [24] [25] [26] aminoglycosides, macrolides [21] [22] [23] [24] and tetracyclines. 21, 23 Although all six studies found significant overall decreases in antibiotic consumption (as expressed by DDD and number of weekly antibiotic prescriptions), one study 24 found increases in macrolides and penicillin prescriptions. Of the six studies, two investigated the link between antibiotic consumption with resistance rates of Streptococcus pneumoniae and Helicobacter pylori, and found mixed results.
The remaining five studies evaluated the restriction of antibiotic purchases without a prescription. Four of the studies found reductions in antibiotic consumption after implementation, 11, 12, 16, 27 while one study found no changes in antibiotic consumption. 28 All results were expressed in DDD.
Separation of antibiotic prescribing from dispensing
Two studies reported the impact of separating drug prescribing from drug dispensing in primary care to disincentivize profit making from prescribing. 29, 30 After implementation of the separation policy in both countries, reductions in antibiotic use, measured in DDD, and prescription were observed. However, in one study, this effect diminished over time and there was no significant reduction in overall antibiotic expenditure.
Campaigns for healthcare professionals
Six studies described campaigns for healthcare professionals in five countries. Campaigns included disseminating flyers and toolkits, 18, 22, 31, 32 conducting workshops and seminars on antibiotic prescription, 22, 31, 33, 34 providing individual prescribing feedback, [31] [32] [33] promoting antibiotic prescribing guidelines in medical school education 32 and sharing experiences among healthcare professionals. 34 Outcome measures to evaluate the effectiveness of these campaigns included the number of 32, 33 and expenditure on antibiotic prescriptions per 1000 inhabitants per month. 32 Four studies showed overall decreases in the number of antibiotic prescriptions per physician at the primary care level, 22, [31] [32] [33] especially in prescribing for respiratory tract infections. One study found no significant changes in overall physician antibiotic prescribing post intervention, although there were increases in prescriptions for both amoxicillin and penicillin. 34 
Decreasing the demand for antibiotics
We found 13 studies from 10 countries describing national public education campaigns to increase awareness about appropriate antibiotic use, hand hygiene and vaccination. These included media campaigns using booklets, exhibits, flyers, posters, websites, newspapers, television or radio spots. 18, 19, 31, 32, [35] [36] [37] [38] [39] Other platforms were also used to raise awareness about antibiotics, such as health information workshops and seminars in the community, 18, 22, 32, 40 childcare centres, primary schools and nursing homes. 31, 34 In addition to messages about antibiotic awareness, there were also hand hygiene campaigns for the prevention of nosocomial infections, 19 and introduction of influenza vaccines for children. 33 Outcome measures used to evaluate these campaigns included the number of reimbursed antibiotic packages, number of prescriptions per physician, volume of antibiotics distributed to retail outlets per capita, percentage of consultations resulting in antibiotic prescriptions and DDD. Using these measures, 10 studies found overall decreases in antibiotic consumption. Of these, two studies found notable decreases only during and immediately after the intervention period, 35, 40 two studies found decreases in antibiotic prescriptions for upper respiratory tract infections, 39 including nasopharyngitis and influenza, 33 and one study showed that the overall decrease was driven mostly by penicillin, macrolides and cephalosporins. 38 One study 34 found no overall change in antibiotic consumption (in DDD), but reported decreased consumption of macrolides, offset by increased consumption of amoxicillin and penicillin. Only one study 19 linked antibiotic consumption with resistance rates and found reductions in penicillin-, tetracycline-and macrolideresistant S. pneumoniae.
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Heterogeneity in outcomes and outcome measures
While individual studies in our review showed that national programmes had a positive impact on antibiotic use, it was challenging to evaluate the impact across time and geography owing to the heterogeneity in outcome measures used to quantify the impact of the programmes. Differences in programme Systematic review 20 11 Allouch et al. • Highest increase in prescribing was established for macrolides (1.05 versus 1.64 DDD); penicillins were also prescribed more frequently (6.41 versus 6.56 DDD), but other subgroups were prescribed less frequently (cephalosporins and quinolones) 19 Cheng et al. Systematic review JAC outcomes between settings could stem from differences in study designs, data collection methods and the diverse number of outcome indicators used. The WHO recommends use of DDD to assess and compare trends in drug consumption between population groups. 41 However, only 10 studies used this outcome measure (Figure 4 ).
Systematic review
Discussion
In our systematic review of responsible use initiatives that have been implemented at the national and/or subnational level to address antibiotic resistance, we identified 34 articles that detailed interventions carried out in 21 high-and upper-middle-income countries. These interventions addressed both access to and demand for antibiotics, with the most common outcome measure of impact being changes in antibiotic consumption. Heterogeneity of study designs, populations, analytical strategies and effect measures meant it was not possible to conduct a meta-analysis. However, overall evidence suggested that interventions were effective in reducing antibiotic consumption in different countries to varying degrees.
However, summarizing evidence of the impact of national interventions from our review was challenging, because studies used a wide range of evaluation and outcome measures, such as compliance rates, resistance rates, general knowledge and perceptions surrounding antibiotic use and antibiotic resistance, and population levels of antibiotic consumption. The heterogeneous outcome measures used to evaluate the effectiveness of the intervention made comparison of results challenging and could pose potential difficulties in decision making or implementation of interventions.
While antibiotic consumption was the most common type of outcome reported, it was also measured in a number of different ways, including prescription rates, sales value or volume, number of prescriptions and DDD. Due to variability in specific outcome measures used, only 10 comparable studies evaluating the impact of national programmes on DDD were available. Standardized outcomes and outcome assessment tools would greatly enhance capacity to monitor global progress in addressing AMR, and allow better assessments of intervention effectiveness in different settings.
Additionally, although establishing a direct link between antibiotic consumption and resistance rates is a crucial aspect of Systematic review evaluating national initiatives, we found only five studies in our review linking population-level antibiotic consumption to resistance levels, and these reported mixed results; in some studies, decreased antibiotic consumption did not lead to lowered resistance rates. Establishing an association between antibiotic consumption and resistance rates could help to determine the extent to which reducing antibiotic consumption is an effective intervention, as well as to assess how this compares with other types of interventions, such as improving vaccination coverage and reducing animal antibiotic use. However, the evidence on this remains limited. There were other challenges in evaluating the success of national-or subnational-level AMR interventions. First, most of the studies included in our review were before-after evaluations. As such, secular changes independent of the intervention might have affected outcomes, such as changes in vaccination policies, or improvements in medical education. Second, reductions in overall population-level antibiotic consumption may not be synonymous with reductions in inappropriate antibiotic use. It was not possible from these data to determine how much inappropriate use was reduced by specific interventions. Further, comparison across countries was challenging as studies were done over different timescales and at different timepoints. Lastly, as most of the evaluations included in our review were not long term, it was difficult to assess whether reduction in antibiotic consumption from the intervention was sustained over time, whether it led to other adverse outcomes (e.g. increased prescribing of third-line antibiotics) or whether antibiotic consumption bounced back after a certain time period.
Strengths and limitations
In interpreting evidence from these national interventions, several limitations should be borne in mind. We were unable to exclude publication bias or reporting bias, which might have impacted the validity and generalization of our conclusions. Very few studies included in our review showed limited or no impact post intervention; the majority of them were examples of interventions that had a positive impact. We were also unable to identify evaluations of national programmes that were not published. Additionally, all the published studies evaluating national implementation of AMR interventions came from high-and upper-middle-income countries, despite the fact that increases in antibiotic consumption are largely driven by increased demand in LMICs. 2 Previous evidence has shown that LMICs have different priorities and contextual issues, such as health system processes, patient demand, varying Systematic review JAC cultures of care, availability of universal access to quality antimicrobials, laboratory infrastructure and surveillance systems. 42, 43 In these settings, multipronged interventions combining different restrictive and enabling strategies are more likely to be effective. 44 Although we were unable to review unpublished evidence, we sought to minimize potential biases due to language and geography as much as possible, by not applying any language restrictions in our review, and searching smaller, more regionally focused databases (e.g. WPRIM) to capture regional or geographically focused research that may not have been indexed in larger, standard academic databases. Similar to a preceding study, 44 this review sought to bring together evidence on the types of government policy interventions and options in addressing AMR. One notable strength of this review is the focus on the population impact of evaluated national interventions to address AMR. This has important policy implications, because although the efficacy of many interventions to address AMR may have been determined in idealized trial conditions in specific settings, it is difficult to generalize their impact, even if they can be scaled up nationally. Published evaluations of national interventions using standardized methods should form a key component of national action plans to address AMR, so that information on what types of interventions work in different settings can be readily shared and adapted by other countries.
Conclusions
Based on the available evidence from primarily high-income countries, our systematic review highlights that strategies to reduce inappropriate demand and access to antibiotics appear to have a quantifiable impact primarily on antibiotic consumption, but more evidence is needed on the long-term impacts of these interventions, such as increases in the consumption of antibiotic subtypes, impacts on prevalence of antibiotic-resistant organisms, as well as the health and economic burden of these infections. It is also challenging to generalize interventions such as restricting access to non-prescription antibiotics to other settings where there may not currently be an adequate number of qualified prescribers in primary care, and where there may be adverse consequences in terms of restricting access to necessary antibiotics. More evidence is needed on the types of interventions that are relevant and effective in these settings. In addition, harmonizing the use of standardized outcome measures in the evaluation of national programmes addressing AMR is crucial to enable comparisons of interventions that are carried out in different settings, longer term and across different populations.
